Editas Medicine, Inc. (Nasdaq: EDIT) named Dan Ory, M.D., as chief medical officer, effective Sept. 8, 2026, according to a press release from the Cambridge, Mass.-based gene editing company.

Dr. Ory brings more than 25 years of experience in cardiovascular medicine and genetic medicine development. He will oversee Editas's clinical development strategy and operations, with a focus on advancing EDIT-401, the company's lead in vivo development candidate for hyperlipidemia, toward clinical trials.

Before joining Editas, Dr. Ory served as chief medical officer at Arbor Biotechnologies, where he led clinical development for an in vivo gene editing program. Prior to that role, he was chief medical officer at Casma Therapeutics, overseeing clinical programs in rare genetic and neurodegenerative diseases.

Before moving to industry, Dr. Ory spent more than two decades at Washington University School of Medicine in St. Louis as the Alan A. and Edith L. Wolff Professor of Cardiology, conducting research in cholesterol metabolism and Niemann-Pick disease type C. He also co-founded Vtesse Therapeutics, a rare disease company.

Dr. Ory holds an A.B. from Harvard College and an M.D. from Harvard Medical School. He completed postdoctoral training at the Whitehead Institute at MIT, an internal medicine residency at Brigham and Women's Hospital, and a cardiology fellowship at Massachusetts General Hospital. He has authored more than 160 peer-reviewed publications and holds multiple patents in cardiovascular and rare disease research.

"Dan joins Editas at an exciting time as EDIT-401 nears clinical development for the potential treatment of hyperlipidemia," said Gilmore O'Neill, M.B., M.M.Sc., president and chief executive officer of Editas Medicine.